SLC5A2 and metabolic dysfunction-associated steatohepatitis: Therefore, in this study, we used medaka NASH model to examine the effect of tofogliflozin (Tofo), a highly specific SGLT2 inhibitor 23, on fatty infiltration and the fibrotic changes in the liver along with BW, liver weight (LW), and hepatotoxicity.